Global Regulators Issue Advice On Clinical Comparability Of Biosimilar MAbs
Comparative Clinical Studies Should Support Demonstration Of Biosimilarity
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
You may also be interested in...
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.
Regulators in the EU have decided on specific arrangements they plan to employ if sponsors detect and report nitrosamine impurities in their products being sold on the market.
The European Medicines Agency is exploring the feasibility and utility of contacting patients’ organizations for their input as soon as its medicines evaluation committee starts reviewing a new drug.